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Abstract: A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after
6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in
chronic myeloid leukemia (CML) patients. In this study, we investigated the reliability of multiple
BCR-ABL1 thresholds in predicting treatment outcomes for 184 subjects diagnosed with CML and
treated with standard-dose imatinib mesylate (IM). With a median follow-up of 61 months, patients
with concordant BCR-ABL1/ABL1IS transcripts below the defined thresholds (10% at 3 months and
1% at 6 months) displayed significantly superior rates of event-free survival (86.1% vs. 26.6%) and
deep molecular response (≥MR4; 71.5% vs. 16.1%) compared to individuals with BCR-ABL1/ABL1IS
levels above these defined thresholds. We then analyzed the outcomes of subjects displaying
discordant molecular transcripts at 3- and 6-month time points. Among these patients, those with
BCR-ABL1/ABL1IS values >10% at 3 months but <1% at 6 months fared significantly better than
individuals with BCR-ABL1/ABL1IS <10% at 3 months but >1% at 6 months (event-free survival 68.2%
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vs. 32.7%; p< 0.001). Likewise, subjects with BCR-ABL1/ABL1IS at 3 months >10% but <1% at 6 months
showed a higher cumulative incidence of MR4 compared to patients with BCR-ABL1/ABL1IS <10% at
3 months but >1% at 6 months (75% vs. 18.2%; p < 0.001). Finally, lower BCR-ABL1/GUSIS transcripts
at diagnosis were associated with BCR-ABL1/ABL1IS values <1% at 6 months (p < 0.001). Our data
suggest that when assessing early molecular responses to therapy, the 6-month BCR-ABL1/ABL1IS
level displays a superior prognostic value compared to the 3-month measurement in patients with
discordant oncogenic transcripts at these two pivotal time points.
Keywords: chronic myeloid leukemia; BCR-ABL1; imatinib mesylate; European Leukemia Net;
early molecular response
1. Introduction
Chronic myeloid leukemia (CML) is characterized by a unique cytogenetic marker, the Philadelphia
(Ph) chromosome, arising from the reciprocal translocation between the long arms of chromosomes
9 and 22 [1]. In turn, the Ph chromosome generates the BCR-ABL1 fusion chimeric gene, encoding
an oncoprotein with constitutive tyrosine kinase activity that alters the proliferation rate, survival
signaling, immunological interactions, and cytoskeletal dynamics of the hematopoietic stem cell [2–7].
The introduction of the tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) has radically improved the
outcome of chronic phase CML patients by generating unprecedented rates of complete hematological
(CHR) and cytogenetic (CCyR) responses and deep molecular responses (MR) [8,9]. Despite these
excellent results, IM resistance is often detected in patients failing to achieve an optimal response
(OR) as defined by the current European Leukemia Net (ELN) recommendations [10]. IM resistance
includes both BCR-ABL1-dependent [11–13] and BCR-ABL1-independent mechanisms [14,15] that
may be prevented or overcome by second- (2G) or third-generation (3G) TKIs such as dasatinib (DAS),
nilotinib (NIL), bosutinib (BOS) and ponatinib (PON). Moreover, non-ABL1-directed inhibitors and
immunological-targeting approaches are currently being developed as additional treatment strategies
for the disease [16–18].
With the introduction of 2G and 3G TKIs, the early identification of CML patients at high risk
of failing IM treatment has become of pivotal importance. Hence, several clinical prognostic scores
[Sokal and EUTOS long-term survival (ELTS)] have been employed to predict CML response to IM
at the time of diagnosis, thereby recognizing patients that will display inferior overall survival (OS)
rates [19–22]. At the same time, several groups have begun to investigate early molecular parameters
that might distinguish CML patients unlikely to benefit from IM. A seminal paper by Marin et al.
reported that BCR-ABL1/ABL1 transcript thresholds of 10% at 3 months and 1% at 6 months strongly
predict long-term outcomes for CML patients [23]. Subsequently, Hanfstein and colleagues reported
that BCR-ABL1/ABL1IS levels >1% at 6 months were associated with inferior 5-year OS compared to
values <1%, thereby suggesting that BCR-ABL1 transcripts at 6 months predict the response of CML
to IM [24]. This body of evidence has been gradually incorporated into clinical practice. Currently,
both the National Comprehensive Cancer Network (NCCN) and ELN guidelines include the failure
to achieve selected molecular responses, albeit at different time points, as a reason to switch to a
different TKI.
In this complex clinical and molecular scenario, a challenging issue is how to manage patients
who display discordant BCR-ABL1/ABL1IS transcripts (BCR-ABL1/ABL1IS <10% at 3 months but >1% at
6 months or BCR-ABL1/ABL1IS >10% at 3 months but <1% at 6 months) at the 3- and 6-month time
points. In this study, we investigated the clinical implications of these molecular landmarks, in subjects
with discordant transcripts at the 3- and 6-month time points, in order to translate these molecular
data into clinically meaningful information for CML patients receiving IM as first-line treatment for
their disease.
Int. J. Mol. Sci. 2019, 20, 2226 3 of 11
2. Results
2.1. Patient Responses and ELN Outcomes
Patient characteristics are summarized in Table 1. Every patient achieved a CHR, 157 (85.3%)
attained a CCyR, 143 (77.7%) reached a major molecular response (MR3) (median time 10 months;
range, 3–83), and 90 (48.9%) achieved a deep molecular response (MR4) (median time 20.5 months;
range, 6–83). Median follow-up of the accrued population was 61 months (range, 12–90). According to
the 2013 ELN recommendations, 126 (68.5%) patients achieved an optimal response, 39 (21.2%) failed
IM, 10 (5.4%) were classified as “warning”, and 9 (4.9%) discontinued IM due to drug intolerance.
All individuals who discontinued IM because of drug failure or intolerance received 2G TKIs.
Table 1. Patient characteristics (n = 184).
Characteristics %
Follow-Up (Median mo.) 61
Age (Years)
Median 55
Range 20–87
Sex (pts n.)
Male 94 51.1
Female 90 48.9
Sokal Risk Group (pts n.)
Low/Int 146 79.3
High 38 20.7
ELTS Risk Group (pts n.)
Low/Int 163 88.6
High 21 11.4
Transcript Type
e13a2 (b2a2) 74 40.2
e14a2 (b3a2) 92 50
e13a2 and e14a2 18 9.8
Optimal Response (pts n.) 126 68.5
Warning (pts n.) 10 5.4
Intolerant (pts n.) 9 4.9
Failure (pts n.) 39 21.2
ELTS: EUTOS long-term survival.
2.2. Probability of Event-Free Survival and Molecular Response According to BCR-ABL1/ABL1IS Transcripts at
3 and 6 Months
Consolidated data has established that BCR-ABL1/ABL1IS levels of 10% at 3 months and 1% at 6
months are predictive of OS, progression-free survival (PFS), event-free survival (EFS), and CCyR [23,24].
When we stratified patients according to their BCR-ABL1/ABL1IS levels at 3 and 6 months, we found
that 63% of the patients had concordant low transcripts (i.e., <10% at 3 months and <1% at 6 months,
group A) while 15.8% of individuals displayed concordant high transcripts (i.e., >10% at 3 months and
>1% at months, group D). EFS probability was 86.1% vs. 26.6% (p < 0.001) in patients respectively
displaying concordant low values (group A) or concordant high values (group D) (Figure 1A).
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Figure 1. Event-free survival (EFS) estimates (A) and cumulative incidence of major molecular response
(MR3) (B) and deep molecular response (MR4) (C) according to BCR-ABL1/ABL1IS transcripts at 3 and
6 months. Patients were divided into four groups according to their BCR-ABL1 expression at the 3 and
6 months. EFS probability (A) and cumulative incidence of MR3 (B) and MR4 (C) were calculated for
each group. Vertical lines indicate censored patients. p-values refer to statistical significance among all
four groups included in the analyses.
The remaining 21.2% of patients displayed discordant transcript values at the 3- and 6-month
time points, as 15.2% presented low (<10%) BCR-ABL1/ABL1IS at 3 months but high (>1%) levels at
6 months (group B), and 6% displayed high (>10%) BCR-ABL1/ABL1IS at 3 months, but low (<1%)
levels at 6 months (group C). Among subjects with discordant BCR-ABL1 expression, group B (<10% at
3 months but >1% at 6 months) achieved significantly lower 6-year EFS as compared to group C (>10%
at 3 months but <1% at 6 months) (32.7% vs. 68.2%, p < 0.001; Figure 1A).
We next evaluated if the 3- or the 6-month BCR-ABL1/ABL1IS levels would predict subsequent
molecular responses to IM. Therefore, we compared the cumulative incidence of MR3 and MR4 in
the four groups described above. As expected, there were significant differences between groups A
and D. Specifically, patients with low transcripts at both 3 and 6 months showed significantly higher
cumulative incidences of both MR3 (94.2% for group A vs. 57.1% for group D, p < 0.001; Figure 1B) and
MR4 (71.5% for group A vs. 16.1% for group D, p < 0.001; Figure 1C). As for patients with discordant
BCR-ABL1/ABL1IS levels, individuals in group B displayed significantly lower cumulative incidences
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of both MR3 (69.4% vs. 100% for group C, p < 0.001; Figure 1B) and MR4 (18.2% vs. 75% for group C,
p < 0.001; Figure 1C).
2.3. Correlation between BCR-ABL1/GUSIS Levels at Diagnosis and BCR-ABL1/ABL1IS Transcripts at 3 and
6 Months
We and Bonecker have demonstrated that quantification of BCR-ABL1 transcripts at diagnosis
by using GUS rather than ABL1 as a reference gene predicts IM response, as this measurement
reflects the amount of BCR-ABL1 transcripts within each leukemic cell [25,26]. Therefore, we explored
the correlation between BCR-ABL1/GUSIS values at diagnosis and BCR-ABL1/ABL1IS levels at 3 and
6 months. We found the highest BCR-ABL1/GUSIS transcripts at diagnosis in groups B (18.5%) and
D (21.3%), which were those that presented BCR-ABL1/ABL1IS values >1% at 6 months. On the
contrary, both groups A and C - displaying BCR-ABL1/ABL1IS values <1% at 6 months - expressed
lower BCR-ABL1/GUSIS at diagnosis (12.9% for group A and 11.6% for group C). These differences
were statistically significant (p < 0.001; Figure 2).
Figure 2. Comparison between BCR-ABL1/GUSIS levels at diagnosis and BCR-ABL1/ABL1IS transcripts
at 3 and 6 months. BCR-ABL1/GUSIS levels were determined for each group and depicted as boxplots
delimited by the 25th (lower) and 75th (upper) percentile. Horizontal lines above and below each
boxplot indicate the 5th and 95th percentile, respectively. Thick lines in each boxplot represent median
BCR-ABL1/GUSIS in each patients group. The p-value above the figure refers to statistical significance
among all four groups included in the analysis while p-values displayed inside the figure refer to
statistical significance among the population groups indicated by the bracket (comparison between
groups A and D: p < 0.001; comparison between groups C and D: p = 0.025).
2.4. Correlation between Risk Scores at Diagnosis and BCR-ABL1/ABL1IS Transcripts at 3 and 6 Months
Multiple findings have established that low Sokal and ELTS scores are associated with better
OS [10,21,22]. We calculated that in our patient cohort, the Sokal and ELTS risk categories correlated
with high or low BCR-ABL1/ABL1IS transcripts at 3 and 6 months. Patients were subdivided into two
categories according to their Sokal or ELTS scores (to perform a binomial analysis, low and intermediate
risk were grouped together and compared to high risk) and were then stratified into the four previously
described groups (A–D) according to their BCR-ABL1/ABL1IS levels at 3 and 6 months. By considering
the Sokal score, we found a significant correlation in groups with concordant BCR-ABL1/ABL1IS
transcripts at 3 and 6 months (p < 0.02782; Table 2). Specifically, the group with the best outcome
(A) presented a significantly higher percentage of low-/intermediate-risk patients as compared to the
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group (D) with the worst outcomes (p < 0.004). In groups with discordant transcripts, we found that
individuals with BCR-ABL1/ABL1IS levels >1% at 6 months (group B) displayed a three-fold greater
number of subjects with a high Sokal risk as compared to individuals with BCR-ABL1/ABL1IS levels
>10% at 3 months (group C; 15.8% vs. 5.3%). However, these differences were not statistically significant.
When we repeated this analysis considering the ELTS score, we again found a significant correlation
between different risk groups and patients displaying concordant BCR-ABL1/ABL1IS transcripts at
3 and 6 months (p < 0.00592; Table 2). In details, more patients with low BCR-ABL1 expression at
both time points (group A) presented low/intermediate ELTS scores compared to subjects with higher
BCR-ABL1 levels at 3 and 6 months (group D; p = 0.0055). No significant correlation was achieved in
groups with discordant BCR-ABL1 transcripts at the two time points, possibly due to the low number
of patients in each of these patient subsets.
Table 2. Association between risk scores and BCR-ABL1/ABL1IS at 3 and 6 months.
BCR-ABL1/ABL1IS
Sokal Risk
p
Low/Intermediate Risk (%) High Risk (%)
n = 146 n = 38
<10% @ 3 mo.
<1% @ 6 mo. 98 (67.1) 18 (47.3)
0.02782<10% @ 3 mo.
>1% @ 6 mo. 22 (15) 6 (15.8)
>10% @ 3 mo.
<1% @ 6 mo. 9 (6.1) 2 (5.3)
>10% @ 3 mo.
>1% @ 6 mo. 17 (13.8) 12 (31.6)
BCR-ABL1/ABL1IS
ELTS Risk
p
Low/Intermediate Risk High Risk
n = 163 n = 21
<10% @ 3 mo.
<1% @ 6 mo. 105 (64.4) 11 (52.4)
0.00592<10% @ 3 mo.
>1% @ 6 mo. 27 (16.6) 1 (4.8)
>10% @ 3 mo.
<1% @ 6 mo. 11 (6.8) 0 (0)
>10% @ 3 mo.
>1% @ 6 mo. 20 (12.2) 9 (42.9)
3. Discussion
Quantification of BCR-ABL1/ABL1IS transcripts after 3 and 6 months of TKI therapy has become
routine practice for the management of CML, as BCR-ABL1 levels below the conventional 10%
(at 3 months) and 1% (at 6 months) thresholds are associated with higher probabilities of achieving
excellent failure-free survival (FFS), EFS, PFS, and OS [23,24,27]. As expected, in this report,
we confirmed that patients displaying BCR-ABL1/ABL1IS transcripts below the indicated thresholds at
both the 3- and 6-month landmarks presented superior outcomes compared to those with BCR-ABL1
transcripts above the 10% and 1% values. However, we also wanted to investigate the clinical impact
of BCR-ABL1/ABL1IS transcripts when the values measured at the 3- and 6-month time points were
discordant: i.e., a satisfactory (<10%) value followed by an unsatisfactory one (>1%) or vice versa.
A previous publication by the Hammersmith group, authored by Neelakantan and colleagues, showed
that when the 3 and 6 months transcripts were discordant, the 3-month levels displayed a superior
prognostic value compared to the 6-month measurement [28]. Interestingly, we found an opposite
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result in our patient cohort, since in subjects with discordant 3 and 6-month transcripts, the latter were
predicted to be significantly more responsive to treatment compared to the former. This discrepancy
might be explained by differences in the number of low (39.9% vs. 28.9%) and high (20.7% vs. 28.9%)
Sokal risk patients included in our study compared to the Hammersmith paper. Indeed, a population
with a less aggressive disease, as described by a low Sokal score, would probably includes individuals
with oncogenic transcripts >10% at 3 months that will continue to exhibit declining transcripts over
time, therefore achieving additional benefit from further treatment with the same TKI. By contrast,
a population with a more aggressive disease (high Sokal score) will probably include individuals
displaying BCR-ABL1/ABL1IS transcripts >10% at 3 months that have already acquired resistance to IM
and are unlikely to benefit from additional treatment with the same drug. This can justify the lower
predictive value of BCR-ABL1 transcripts at the 6-month time point in the UK cohort. This hypothesis
is in line with the different number of patients included in the group with high BCR-ABL1 transcripts
at 3 months but low levels at 6 months in our series (6%), compared to the UK cohort (2%). It should
also be noted that our results are in agreement with those previously published by the Korean group,
indicating that BCR-ABL1 transcripts below the 1% threshold at 6 months are a reliable molecular
parameter capable of identifying a subset of patients that will benefit from their assigned treatment
even if their BCR-ABL1 levels at 3 months were above the 10% value [29]. Unfortunately, we could
make no comparisons between the data summarized in the UK and Korean studies and our reported
findings concerning the ELTS score, as this parameter only became available in 2016 and was therefore
not included in previously published manuscripts.
Both the NCCN and the ELN recommendations for the management of CML patients require
disease molecular evaluations at 3, 6, and 12 months during TKI treatments. In our previous study,
we demonstrated that baseline quantification of BCR-ABL1 expression is a useful parameter to
discriminate, at diagnosis, patients unlikely to benefit from standard-dose IM [25]. In the current
report, we wanted to validate these data by correlating baseline BCR-ABL1 quantification with the
molecular transcripts detected at 3 and 6 months. We confirm a direct association between BCR-ABL1
expression levels at diagnosis and IM response, as patients with BCR-ABL1 values <1% at 6 months
(groups A and C) were those expressing lower BCR-ABL1 transcripts at diagnosis.
Finally, several clinical trials have demonstrated that patients who achieve and maintain a deep
molecular response (≥MR4) could be considered for TKI discontinuation as they may remain in
treatment-free remission (TFR), even after drug cessation. TFR is an attractive possibility because
of relief from TKI toxicities, desire to plan a pregnancy, and general improvement in quality of life.
Moreover, even with the advent of generic IM, TKI discontinuation may greatly relieve the financial
toxicity associated with CML treatment [30]. Our data suggest that molecular responses at 3 and
6 months after IM may predict which patients will achieve greater benefit from the drug and should,
therefore, be considered for treatment-free remission.
4. Materials and Methods
4.1. Patient Characteristics and Treatment
Between 1 June 2010, and 31 December 2017, a total of 184 adult patients with chronic phase (CP)
CML were accrued to this study. Diagnosis of CP-CML was defined by conventional criteria. No prior
treatment for CML other than hydroxyurea was allowed.
All patients received IM 400 mg daily as first-line therapy. The drug was discontinued in the
presence of grade 3/4 toxicities with treatment resumed after toxicity reduction to grade 1 or complete
resolution. IM responses were evaluated according to the 2013 ELN criteria [10]. Only those patients
who had BCR-ABL1 transcripts at 3 and 6 months were included in this study.
The research ethics committee (Supplementary Materials) of each recruiting institution reviewed
and approved the study protocol on 10 October 2005 and all patients gave written informed consent
for the data to be used in this analysis.
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4.2. Hematologic, Cytogenetic, and Molecular Analyses Response
A complete hematological response was defined as previously reported [31]. Cytogenetic analysis
was performed at diagnosis, at 3 and 6 months, and then every 6 months until a CCyR was achieved.
At least 20 bone marrow cell metaphases were evaluated through conventional G-banding analysis.
CCyR was defined as the failure to detect any Philadelphia chromosome (Ph)-positive metaphases in
two consecutive examinations [32]. Confirmed detection of one or more Ph-positive metaphases after
acquiring a CCyR was considered a cytogenetic relapse.
BCR-ABL1 and ABL1 expression were measured from peripheral blood (PB) samples drawn at
diagnosis and then every three months using real-time PCR (qPCR) as previously described [25].
ABL1 was used as the reference gene at any time point other than diagnosis. In addition, at diagnosis,
BCR-ABL1 expression was measured by using GUS as a housekeeping gene as it is a more appropriate
reference gene for specimens expressing high BCR-ABL1 [33]. All samples were processed for
nucleic acid extraction in the Center of Experimental Oncology and Hematology of the A.O.U.
Policlinico-Vittorio Emanuele, as previously described [34]. qPCR determinations for BCR-ABL1/ABL1
and BCR-ABL1/GUS were converted to the international scale (IS), as previously reported [25]. MR3 was
defined by BCR-ABL1/ABL1IS ≤0.1% (3-log reduction from the standardized baseline) [35,36], while MR4
was defined by BCR-ABL1/ABL1IS ≤0.01% (≥4-log reduction from standardized baseline) [35,36].
qPCR determinations were considered of appropriate quality only in the presence of no less than
24,000 GUS copies or 10,000 ABL1 copies, as previously reported [36].
4.3. Statistical Analysis
Probabilities of event-free and failure-free survival, and cumulative incidence (CI) of different
molecular responses, were calculated using the Kaplan–Meier method. Statistical significance
between different Kaplan–Meier curves was evaluated using the Mantel–Haenszel test, as previously
described [37]. Differences in BCR-ABL1/GUSIS, at diagnosis, in the four groups of patients defined
according to their BCR-ABL1/ABL1IS levels at 3 and 6 months, were calculated using the ANOVA test,
followed by the Tukey HSD post hoc test. Events included in our definition of EFS were death from
any cause, a progression from chronic phase, IM failure according to the 2013 ELN recommendations,
and development of intolerance. FFS was defined as survival without evidence of drug failure
according to the latest ELN recommendations.
Differences in the occurrence of specific risk scores (Sokal or ELTS) among the four groups of
patients were assessed using the Fisher exact test computing two-sided p-values with 95% confidence
intervals. All statistical analyses were performed using R software [38].
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/20/9/2226/s1.
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Abbreviations
ABL Abelson murine leukemia
BOS bosutinib
CCyR complete cytogenetic response
CML chronic myeloid leukemia
CHR complete hematological response
DAS dasatinib
ELN European Leukemia Net
ELTS EUTOS long-term survival
EFSFFS event-free survivalfailure-free survival
GUS β-glucuronidase
IM imatinib mesylate
MR molecular responses
NCCN National Comprehensive Cancer Network
NIL nilotinib
OR optimal response
OS overall survival
Ph Philadelphia chromosome
PON ponatinib
PFS Progression-free survival
TKI tyrosine kinase inhibitor
TFR treatment-free remission
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